Metformin: A promising clinical therapeutical approach for BPH treatment via inhibiting dysregulated steroid hormones-induced prostatic epithelial cells proliferation

• DOI: 10.1016/j.jpha.2023.08.012
• Publication Date: 2023-08-22T06:32:48Z
• Authors: Tingting Yang; Jiayu Yuan; Yuting Peng; Jiale Pang; Zhen Qiu; Shangxiu Chen; Yuhan Huang; Zhenzhou Jiang; Yilin Fan; Junjie Liu; Tao Wang; Xueyan Zhou; Sitong Qian; Jinfang Song; Yi Xu; Qian Lu; Xiaoxing Yin
• Keywords: 0301 basic medicine; 03 medical and health sciences; Benign prostatic hyperplasia; DHT; YAP1-TEAD4 heterodimer; Proliferation; Sex steroid hormones homeostasis; Original Article; Therapeutics. Pharmacology; RM1-950; Metformin

The occurrence of benign prostate hyperplasia (BPH) was related to disrupted sex steroid hormones, and metformin (Met) had a clinical response hormone-related gynaecological disease. However, whether Met exerts an antiproliferative effect on BPH via hormones remains unclear. Here, our study showed that along with prostatic epithelial cell (PEC) proliferation, were dysregulated in the serum patients. As major contributor elevated DHT significant positive relationship characteristics Activation AMPK by restored hormone homeostasis exerted effects against DHT-induced proliferation inhibiting formation androgen receptor (AR)-mediated YAP1-TEAD4 heterodimers. Met's anti-proliferative blocked inhibitor or YAP1 overexpression DHT-cultured BPH-1 cells. Our findings indicated would be promising therapeutic approach for hormone-induced PEC proliferation.